Slow-Release and Extended-Release Ketamine Tablet Formulations

Most compounded ketamine tablets dispensed today are immediate-release formulations — they dissolve quickly in the stomach and the drug is absorbed over a relatively short window. However, slow-release and extended-release ketamine formulations are an area of growing interest, offering the potential for more sustained blood levels, fewer daily doses, and possibly improved tolerability.

Immediate-Release vs. Extended-Release: The Basics

Immediate-Release (IR) Tablets

Standard ketamine tablets release their entire drug content within minutes of reaching the stomach. This produces a characteristic pharmacokinetic profile:

• Rapid absorption — peak plasma levels (Cmax) reached within 30–60 minutes
• Relatively high peak — the entire dose is absorbed in a compressed timeframe
• Shorter duration — blood levels decline over the next 2–4 hours
• Multiple daily doses often required for sustained effect

Extended-Release (ER) / Slow-Release (SR) Formulations

Extended-release formulations are engineered to release ketamine gradually over a longer period. The goal is:

• Lower peak levels — reducing side effects associated with high Cmax values
• Sustained therapeutic levels — maintaining effective blood concentrations over 6–12 hours
• Fewer doses per day — improving convenience and adherence
• Smoother experience — less pronounced onset and offset of effects

How Slow-Release Formulations Work

Several technologies can be used to create extended-release ketamine tablets:

Matrix Systems

The most common approach for compounded ER ketamine tablets. The drug is embedded in a polymer matrix (often hydroxypropyl methylcellulose or similar) that swells in gastric fluid, forming a gel layer. Ketamine diffuses slowly through this gel layer over hours.

Advantages: Relatively simple to compound, consistent release profile
Limitations: Release rate can be affected by food, GI motility, and pH changes

Coated Systems

Multi-layer or reservoir coatings surround the drug core, controlling the rate at which gastric fluid reaches the ketamine. These can include:

• Enteric coatings — resistant to stomach acid, releasing drug only in the higher-pH environment of the small intestine
• Rate-controlling membranes — semi-permeable coatings that allow water in and drug out at a controlled rate
• Multi-particulate systems — multiple small pellets within a capsule, each coated to release at different times

Osmotic Systems

More sophisticated (and less commonly compounded), these use osmotic pressure to push ketamine through a laser-drilled hole in an insoluble shell at a constant rate. This technology delivers the most consistent release profile but is typically only available from pharmaceutical manufacturers.

Current Availability

As of early 2026, there is no FDA-approved extended-release ketamine tablet on the market. Available options include:

Compounded ER Tablets

Some specialty compounding pharmacies can prepare extended-release ketamine tablets using matrix technology. These are available by prescription and are prepared according to USP compounding standards. Quality varies between pharmacies, and potency testing is particularly important for ER formulations where inconsistent matrix preparation could lead to dose dumping.

If you use a compounding pharmacy for ER tablets, verify their quality standards. See our mail-order pharmacy guide for tips on evaluating compounding pharmacies.

Investigational Formulations

Several pharmaceutical companies are developing proprietary extended-release ketamine formulations for specific indications:

• Treatment-resistant depression — ER formulations designed to maintain antidepressant-level blood concentrations with once-daily dosing
• Chronic pain — formulations targeting sustained NMDA receptor blockade for pain conditions
• PTSD — investigational products combining ketamine with specific release technologies

These remain in clinical trials and are not yet commercially available.

Pharmacokinetic Differences

The practical differences between IR and ER ketamine tablets are significant:

The lower peak levels with ER formulations are clinically meaningful. Many of ketamine's most bothersome side effects — dissociation, dizziness, nausea — are related to the Cmax rather than the total drug exposure. By flattening the peak, ER formulations may allow patients to tolerate higher total daily doses with fewer side effects.

For more on how ketamine's peaks and troughs affect the patient experience, see our article on peak plasma concentrations.

Potential Benefits of Slow-Release Formulations

Improved Adherence

Taking medication multiple times daily is a significant barrier to adherence, particularly for patients managing chronic conditions. Studies across many medication classes consistently show that once-daily dosing improves long-term adherence compared to twice- or thrice-daily regimens. For more on adherence, see our adherence studies article.

Reduced Side Effects

The most commonly reported side effects of oral ketamine — dissociation, dizziness, cognitive clouding, and nausea — are often most pronounced in the 30–90 minutes after taking an immediate-release tablet, corresponding to the peak blood level. ER formulations that produce a lower, more gradual peak may significantly reduce these effects.

This could be particularly relevant for:

• Patients who need to function cognitively during treatment (work, childcare, etc.)
• Patients who have discontinued ketamine due to intolerable peak-related side effects
• Patients on higher doses for pain management

More Consistent Therapeutic Levels

For conditions like CRPS or chronic pain where sustained NMDA receptor blockade is the therapeutic goal, the valleys between IR doses represent periods of reduced efficacy. ER formulations help maintain blood levels above the therapeutic threshold for longer periods, potentially improving pain control.

Nighttime Dosing

Some clinicians prescribe ER ketamine tablets at bedtime for patients whose primary complaints include pain-disrupted sleep. The sustained release provides analgesic coverage through the night without the intense peak that might cause problematic dissociation at sleep onset.

Important Cautions

Do Not Crush or Split ER Tablets

This point cannot be emphasized enough. Crushing, splitting, or chewing an extended-release ketamine tablet can release the entire dose at once — a phenomenon called dose dumping. This converts what was designed as a gradual 8–12 hour release into an immediate-release experience at a dose that may be substantially higher than a standard IR tablet.

Dose dumping can cause:

• Intense dissociation
• Excessive sedation
• Cardiovascular changes (elevated heart rate and blood pressure)
• Severe nausea
• Potential safety risks, especially if driving or operating equipment

For more detail, see our guide on crushing or splitting tablets.

Alcohol Interaction

Alcohol can dissolve certain polymer coatings and matrix systems, potentially accelerating drug release from ER formulations. This is another reason to avoid alcohol when taking ketamine tablets. See our alcohol interaction guide.

Switching Between Formulations

If your provider switches you from IR to ER ketamine (or vice versa), the total daily dose may need adjustment. The different absorption profiles mean that the same milligram dose does not produce identical clinical effects. Your provider will guide this transition and may need to titrate the new formulation.

GI Conditions

Patients with conditions that significantly alter GI transit time may have unpredictable absorption from ER formulations:

• Gastroparesis — delayed gastric emptying can cause the tablet to remain in the stomach longer than intended, potentially altering release characteristics
• Short bowel syndrome or rapid transit — the tablet may pass through the absorptive zone before the full dose has been released
• Bariatric surgery — altered GI anatomy can affect ER tablet performance

Discuss any GI conditions with your prescriber before starting an ER formulation.

The Norketamine Question

An interesting pharmacological nuance: ER formulations may produce different norketamine profiles compared to IR tablets. With IR dosing, the rapid absorption creates a bolus of ketamine that is extensively metabolized during first-pass through the liver, producing a high norketamine peak.

ER formulations deliver ketamine more gradually, which may result in:

• A more sustained but lower norketamine level
• A different ketamine-to-norketamine ratio
• Potentially different therapeutic effects, since norketamine has its own pharmacological activity

This is an active area of research. For more on norketamine's role, see our gut absorption science article.

What to Ask Your Provider

If you are interested in slow-release ketamine formulations:

1. "Is an extended-release formulation appropriate for my condition?" — Not all conditions benefit equally from ER dosing
2. "Does your compounding pharmacy offer ER ketamine tablets?" — Not all pharmacies compound this formulation
3. "How does the dosing differ from my current IR tablets?" — Understand the dose conversion
4. "What are the specific instructions for taking ER tablets?" — When to take them, food timing, and what not to do (crush, split, etc.)
5. "How will we monitor the transition?" — Expect closer follow-up during the switch period

Looking Ahead

Extended-release ketamine represents one of the more promising developments in oral ketamine therapeutics. If pharmaceutical-grade ER formulations receive FDA approval for specific indications, it could:

• Standardize dosing and improve quality consistency
• Open potential insurance coverage pathways
• Provide more robust safety data from large clinical trials
• Make oral ketamine more accessible to patients who currently struggle with IR side effects

Until then, compounded ER formulations remain available for patients whose providers determine they are appropriate, prepared by pharmacies with the expertise to produce them reliably.

References

• Extended-Release Drug Delivery: Principles and Applications — Comprehensive review of ER formulation technologies and pharmacokinetics
• Oral Ketamine Pharmacokinetics and Bioavailability — Foundational pharmacokinetic study relevant to both IR and ER oral ketamine
• Dose Dumping from Modified-Release Formulations — NIH-indexed review of risks associated with altered ER dosage forms
• Adherence to Chronic Pain Medications and Dosing Frequency — Research on the relationship between dosing frequency and medication adherence
• NMDA Receptor Antagonists in Chronic Pain: Sustained Blockade — Review of sustained NMDA receptor modulation in pain management